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Abstract 
Background: No ‘gold standard’ exists for single-agent chemotherapy of human epidermal growth 
factor receptor 2-negative (HER2-negative) metastatic breast cancer (MBC) in the second-line. The 
objective of this systematic review is to identify and appraise overall survival (OS), progression-free 
survival (PFS), time to progression (TTP) and Grade III+ adverse event evidence for single-agent 
chemotherapy in this setting. 
Methods: MEDLINE, Embase and the Cochrane Library were searched to October 2013, and 
PubMed October 2013 to November 2014. Electronic database searches were supplemented with hand 
searching of reference lists and conferences. Eligible randomised controlled trials (RCTs) employed at 
least one single-agent chemotherapy treatment, enrolled HER2-negative or unselected MBC patients 
who had progressed following first-line chemotherapy within the metastatic setting, and reported 
outcomes of interest for the second-line setting. 
Results: Fifty-three RCTs were included in total, with most containing mixed populations by HER2 
status and treatment line. Fourteen studies reported data specifically for second- and later-line 
treatment within the metastatic setting. Median overall survival (OS) in most trials was 8–13 months. 
Only one trial reported a significant difference between studied interventions in the second-line 
metastatic setting: nab-paclitaxel (n=131) conferred a statistically significant OS advantage vs three-
weekly paclitaxel (n=136) (median OS 13.0 vs 10.7 months, respectively; hazard ratio 0.73, p=0.024) 
and improved overall safety.  
Conclusion: One RCT demonstrated significant benefit in this setting in confirmed HER2-negative 
MBC alongside favourable safety. Treatment line terminology was imprecise. To reliably inform 
patient treatment decisions, quality-of-life data are needed and precise OS estimation according to 
underlying patient characteristics. 
Key words: Second-line; HER2-negative; metastatic breast cancer; monotherapy; systematic review; 
randomised controlled trials  
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Introduction 
Breast cancer is the most commonly diagnosed cancer and a leading cause of cancer mortality in 
women in both developed and developing countries. The World Health Organization estimates that 
more than 508,000 women died of breast cancer in 2011 [1]. Approximately 5–10% of women have 
metastatic breast cancer (MBC) at diagnosis [2], while a further 20–40% of breast cancer patients will 
go on to develop MBC [3]. MBC is an incurable disease with a median survival of 2–3 years [4-6]. 
Therefore, the aims of treatment are palliative: to control symptoms in order to maintain and improve 
patient quality of life (QoL) and, where possible, prolong survival [4]. 
MBC is a highly heterogeneous disease varying in tumour presentation and in biological and clinical 
behaviour. There are several molecular subtypes of MBC. Tumours may vary by hormone receptor 
status (i.e. oestrogen receptor [ER] and progesterone receptor [PR] status) and human epidermal 
growth factor receptor 2 [HER2] status [7]. Approximately two-thirds of breast cancer tumours 
express ER and/or PR receptors [8]. Hormone receptor positive tumours can be further sub-divided 
into luminal A and luminal B molecular subtypes, with luminal B tumours having a poorer prognosis 
(median survival 30 vs 45 months) [6, 9]. Treatment options include hormonal therapies and selective 
oestrogen receptor modulators [8]. About 15–20% of newly diagnosed breast cancers over-express 
HER2 (HER2+) [10-12]. These patients are treated with HER2-targeting agents (e.g. trastuzumab), in 
combination with hormonal therapy and/or chemotherapy [10-12]. HER2-targeting therapies have 
been shown to improve survival in patients with MBC [10]. In patients who are HER2-negative, but 
hormone receptor positive with no extensive and/or symptomatic visceral disease, hormone therapy is 
the first-line treatment option. In those patients with visceral involvement, chemotherapy is usually 
the treatment of choice [2, 13]. Triple-negative tumours do not express ER, PR and HER2, and for 
these patients chemotherapy is the main treatment option. According to European Society of Medical 
Oncology (ESMO) guidelines, there are no standard approaches for triple-negative patients requiring 
second- or later-line chemotherapy [2]. Beyond the use of HER2 and hormone receptor status to guide 
treatment, there is currently limited progress. The use of molecular profiles to select appropriate 
treatment options is the subject of intense research and has great potential, but is likely to be sensitive 
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to the emerging plethora of targeted therapies. Chemotherapy options include anthracyclines (e.g. 
doxorubicin, epirubicin), taxanes (e.g. docetaxel, nab-paclitaxel, and paclitaxel), vinca alkaloids (e.g. 
vinorelbine), anti-metabolites (e.g. capecitabine), platinum agents (e.g. cisplatin and carboplatin) and 
eribulin. 
Treatment options for patients with MBC are dependent on several factors including disease burden, 
earlier treatments, response to and time elapsing since last exposure to earlier therapies, and patient 
characteristics and preferences [2, 13, 14]. Due to the heterogeneity of the disease, an individualised 
approach to the treatment of MBC is considered necessary. Following the failure of first-line therapy 
for MBC, the chance of response to subsequent therapy is reduced by approximately 50% with each 
previous regimen received [14]. However, due to the lack of predictive factors for specific agents, in 
some cases it is possible to see a larger than expected therapeutic benefit in second-line and/or further 
lines of therapy. Single-agent chemotherapy is the preferred treatment option in patients without 
severely symptomatic or immediately life-threatening disease [2]. In addition, treatment options in the 
second- and later-line settings are often limited by drug resistance as a result of earlier exposure to 
cytotoxic regimens [15]. For example, patients receiving second-line treatment for MBC will often 
have previously received a taxane and/or anthracycline-based chemotherapy, which may subsequently 
result in treatment-resistant cases of MBC.  
At present there is no ‘gold standard’ of treatment for MBC [14]. Physicians must rely on clinical trial 
data to make decisions regarding the most beneficial course of treatment for patients following first-
line therapy failure [15]. In this respect, well-designed, objective, randomised controlled trials (RCTs) 
are fundamental to informing clinical practice. However, the majority of trials tend to focus on the 
comparison of specific treatments in pre-defined patient populations at a specific phase of disease, and 
also have relatively short follow-up periods, producing MBC populations that are not representative 
of those seen in clinical practice [16]. There is therefore a need for physicians to understand the 
current evidence base for single-agent therapy for HER2-negative MBC second-line treatment. 
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The present systematic review (SR) was conducted in order to qualitatively synthesise the evidence 
base for the treatment of MBC and to make recommendations regarding future trials in this setting. 
Methods 
Search strategy 
The present SR was performed in accordance with Cochrane recommendations [17]. A pre-defined 
SR protocol was produced. The original SR searches were run in the electronic databases of 
MEDLINE, Embase and The Cochrane Library on 17th September 2012. A subsequent update search 
in these databases was conducted on 30th October 2013. A further update was performed in PubMed 
for the period 30th October 2013 to 14th November 2014. 
Additionally, the following sources were hand searched: reference lists of included RCTs; studies 
included in relevant SRs; clinical trials databases; and National Institute for Health and Care 
Excellence (NICE) technology appraisals, evidence reviews and clinical guidelines relating to 
chemotherapy treatment in patients with advanced or metastatic breast cancer. The following 
conference proceedings (2010–2013 inclusive) were searched for trial data without full publications: 
American Society of Clinical Oncology (ASCO); European Cancer Organisation (ECCO); European 
Society of Medical Oncology (ESMO); International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR). 
Eligible studies were Phase II or Phase III RCTs. Studies meeting the inclusion criteria were RCTs 
that had enrolled patients to receive single-agent chemotherapy as a second-line treatment for HER2-
negative advanced or metastatic breast cancer. ‘Second-line’ was defined as patients who had 
received one prior line of chemotherapy treatment in the advanced or metastatic setting. It was 
anticipated that RCTs would be retrieved that contained ‘mixed-lines’ (i.e. combined results for 
patients treated at first-, second- or third-line, etc.); therefore, any studies containing second-line 
treated patients were included, and the proportions of second-line treated patients noted. It was also 
anticipated that some trials would pre-date the period from which HER2 testing began in clinical 
practice. Therefore, the SR included studies where HER2 status of enrolled patients was not reported, 
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as it anticipated that such studies would contain patients who were HER2-negative (albeit at an 
unknown proportion). Trials of exclusively HER2+ patients and of patients who were naïve to 
chemotherapy treatment were excluded.  
Comparators 
The single-agent comparators for the treatment of MBC included in the SR were: taxanes (paclitaxel, 
nab-paclitaxel, docetaxel), vinca alkaloids (vinorelbine, vinblastine, vincristine), platinum-based 
treatments (cisplatin, carboplatin), anthracyclines (doxorubicin, pegylated liposomal doxorubicin 
[PLD], epirubicin) and other monotherapy (capecitabine, gemcitabine, eribulin, melphelan or 
cyclophosphamide) vs any comparator. Nab-paclitaxel is licensed in MBC patients for whom 
anthracyclines are not suitable, so the anthracyclines included here, doxorubicin, PLD and epirubicin, 
would not be direct comparators, but are included as they may still be used in second-line therapy.  
Topoisomerase inhibitors were not included; amrubicin as it is unlicensed in MBC, and irinotecan 
because it is unlicensed in breast cancer. Also excluded were hormonal treatments (aromatase 
inhibitors), marimastat (due to its development having been terminated), tyrosine kinase inhibitors 
(lapatinib, reatinib, afatinib, BMS-754807, sunitinib, pazopanib, dasatinib) and inhibitors of 
downstream targets (everolimus, BKM120, BEZ-235, tanespimycin, retaspimycin, AUY922). 
Outcome measures 
The SR focused on the following efficacy outcomes: overall survival (OS), progression free survival 
(PFS), and time to progression (TTP). Data for QoL and other patient-reported outcomes were also 
sought. The following toxicity outcomes were included: withdrawal from treatment due to toxicity, 
haematological adverse events (AEs), non-haematological AEs, Grade three and four AEs, and 
mortality. 
Data collection 
A reviewer conducted the database searches and screening of citation abstracts for inclusion, 
according to a pre-defined SR protocol. Following abstract screening, full publications of potentially 
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includable studies were retrieved for further review against the protocol eligibility criteria. 
Inclusion/exclusion of citations was verified by another reviewer. Any disputes regarding eligibility 
were referred to a third reviewer. Study methodology, patient characteristics, and clinical outcomes 
data of included studies were extracted into a pre-determined data extraction table produced using 
Microsoft Excel®. Quality appraisal of the elements of selection, attrition, detection, and performance 
bias was performed in accordance with the NICE Guidelines Manual 2009 [18], which assesses risk 
of bias at the study level. 
Results 
A PRISMA flow diagram of the citation screening for the original and updated SRs is shown in 
Figure 1. The original electronic database searches identified a total of 15,356 potentially relevant 
publications, of which 4,285 duplicates were excluded. Subsequently, 11,071 citations were screened 
on the basis of title and abstract. A further 10,979 citations were excluded, leaving 92 citations, the 
full publications of which were acquired. Upon reapplication of the eligibility criteria, a further 49 
citations were excluded, and one citation was included from hand searching. Therefore, the original 
SR identified 44 publications reporting on 43 individual RCTs. The first SR update yielded seven 
further included RCTs; and the PubMed update another three RCTs. Therefore, a total of 53 RCTs 
were included, of which 14 reported data specifically for second- and/or later-line treatment within the 
metastatic setting.  
Study and patient level characteristics of trials enrolling second- and/or later-line patients (n=14) 
Table 1 categorises included RCTs by treatment line, including key trial characteristics. Of the 14 
second- and/or later-line papers, five [19-23] reported data for a purely second-line patient population, 
three [24-26] reported data from mixed-line treatment but provided results for the second-line 
subgroup separately, three [27-29] had unclear second-line status (i.e. it was unclear whether the 
previous therapy had been given in the adjuvant or metastatic setting), two [30, 31] reported data from 
second- or later-line patients, and one [32] reported data from a second- or later-line subgroup 
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separately. The categorisation of the other 39 RCTs as first- or later-line (mixed) patients has been 
tabulated (data not shown, available on request).  
There were five phase II trials, seven phase III and two trials did not report the phase. Considering 
sample size, the greater weight of evidence for effects in second- and/or later-line therapy comes from 
the recent TANIA trial (von Minckwitz et al, 2014; N=494) [19]; Gradishar et al, 2005 (N=268) [32]; 
Keller et al, 2004 (N=301) [31]; and Joensuu et al, 1998 (N=162) [26].  
Only three trials enrolled confirmed HER2-negative patients specifically [19, 27, 29]. Papadimitriou 
et al, 2009 [23] enrolled unselected patients reporting that 21–24% were HER2+, 29–34% HER2-
negative, and 34–42% of unknown HER2 status. Palmieri et al, 2012 [30] also enrolled unselected 
patients but did not report their HER2 status. The other nine trials did not report HER2 status [20-22, 
24-26, 28, 31, 32].  
An overview of the patient characteristics across treatment arms is shown in Table 2. Within trials, 
there were some potential imbalances between treatment arms: the proportion of patients with 
oestrogen or progesterone receptor positivity (ER+ and/or PR+) in Baselga et al, 2012 [29] was 
numerically higher on sorafenib + capecitabine vs capecitabine; the proportion ER+ in Venturino et 
al, 2000 [20] was higher in the vinorelbine monotherapy arm; the proportion of patients with ECOG 
(Eastern Cooperative Oncology Group) status 0 was higher with docetaxel monotherapy vs docetaxel 
+ gemcitabine in Papadimitriou et al, 2009 [23]; median ECOG status was lower in the vinorelbine 
monotherapy arm and the proportion of patients with visceral metastases also lower in Venturino et al, 
2000 [20]; the proportion of patients with visceral metastases was numerically higher on mitomycin 
vs paclitaxel in Dieras et al, 1995 [21]; and median age was slightly higher in the epirubicin arm vs 
doxorubicin in Gasparini et al, 1991 [22].  
There was much variation between trials with regards to the proportion of patients with visceral 
metastases, (Table 2): from 38% in Gasparini et al, 1991 [22] to 95% in Dieras et al, 1995 [21] for any 
visceral metastases; from 19–61% for liver metastases; and 26–61% for lung metastases. There was 
also considerable variation in the number of metastatic disease sites. Hormone receptor status also 
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varied across trials, ER positivity ranging from 30–56%, and PR positivity from 5.6–30%, where 
reported.  
Outcomes reported 
The primary endpoint was OS in two trials [26, 30], PFS in four [19, 27, 29, 31], overall response in 
three [23, 28, 32] and not reported in five papers published between 1990 and 2000 [20-22, 24, 25] 
(Table 1). Safety/toxicity was typically a secondary endpoint, amongst others. Only three papers 
examined QoL as an endpoint: one from Canada [24] provided QLQ-C30 data, one [26] in Finland 
used the Rotterdam Symptom Checklist and the recent, mainly European, TANIA trial [19] did not 
report the patient-reported outcome (PRO) data in the 2014 paper, the authors stating that PRO data 
would be reported separately, as would the final OS analysis and third-line PFS and third-line safety 
after further follow-up of trial patients. Neither Norris et al, 2000 [24] nor Joensuu et al, 1998 [26] 
reported the QoL data separately for the second-line subgroup. 
Overall survival in second- and later-line setting 
Median OS according to treatment line is shown in Table 3 and Table 4; 12 of 14 trials reported OS. 
Ahmad et al, 2013 [28] did not report OS and in Sato et al, 2012 [27] and von Minckwtiz et al, 2014 
[19] median OS had not been reached, i.e. the OS data were immature. Only one trial demonstrated a 
statistically significant difference in OS in the second- and later-line setting: nab-paclitaxel 
demonstrated significantly longer median OS compared with standard paclitaxel 175mg/m2 every 3 
weeks (q3w) (13.0 vs 10.7 months, respectively; hazard ratio [HR] 0.73, p=0.024) in a large (n=268) 
phase III multinational trial performed in USA/Canada, UK and Russia/Ukraine [32].  
In the majority of second-line trials, median survival was from 8–13 months. Absolute survival was, 
however, much longer in the monotherapy arm of Papadimitriou et al, 2009 [23], with median OS 
28 months (95% CI: 15.7, 40.3) on weekly docetaxel (DTX) 40mg/m2 vs 14 months (95% CI: 3, 25) 
on weekly DTX 35mg/m2 + gemcitabine, in spite of the actual median relative dose intensity of 
docetaxel being 0.6 and that of gemcitabine being 0.5. These results should be viewed with caution, 
however, as the trial was relatively small (n=88). The higher proportion of patients with ECOG status 
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0 in the DTX monotherapy arm (71%) compared with the combination arm (56%) may have 
contributed to the longer duration of OS in the monotherapy arm (28 months). The fact that the 
HER2+ patients in this trial also received trastuzumab may have contributed positively to the overall 
OS length in both arms. Median OS was also long in the trial of Baselga et al, 2012 [29], where the 
reportedly second-line subgroup patients had median OS of 23.4 months on capecitabine and 
19 months on capecitabine + sorafenib. The reporting is not clear, however, as to whether second-line 
relates to chemotherapy overall or to the setting within metastatic disease. It may therefore be that this 
subgroup includes patients that were in the first-line metastatic setting. This trial also had a high 
proportion of patients with ECOG status 0 (68.7% in the sorafenib + capecitabine arm and 67.5% in 
the placebo + capecitabine arm) (Table 2) and only enrolled HER2-negative patients (so did not have 
HER2+ patients without trastuzumab treatment). Absolute OS was particularly low in the small 
(n=37) UK phase II trial of Palmieri et al, 2012 [30] on DTX 100mg/m2 weekly (median OS 
7.8 months, 95% CI: 4.8, 11) and on vinorelbine (median 4.9 months, 95% CI: 3.9, 5.8). This may 
have been due in part to more than 80% of patients being third- or later-line within the metastatic 
setting, all patients being anthracycline-resistant and also to patients’ HER2 status being unknown. 
Although this study had OS as a primary objective, no statistically significant difference was observed 
between the arms, although this may have been influenced by the small sample size and extensive 
crossover at progression. 
There was no OS data for weekly paclitaxel (PTX), and the majority of papers unfortunately did not 
report the 95% confidence interval around the median OS estimate. No RCT used modern adjustment 
methods to account for crossover of patients from the control arm, such as Rank Preserving Structural 
Failure Time (RPSFT) or Inverse Probability Censoring Weighted (IPCW) analyses [33]. 
Progression-free survival in second- and later-line setting 
Median PFS was reported in four trials [19, 27, 29, 31, 34]. Three trials demonstrated significantly 
longer PFS: capecitabine + sorafenib (6.4 months) vs capecitabine (4.1 months), HR 0.58 (95% CI: 
0.41, 0.81), p=0.001 [29]; capecitabine + low dose DTX (10.5 months) vs DTX monotherapy before 
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having sequential capecitabine (9.8 months), HR 0.62 (95% CI: 0.40, 0.97), p=0.0342 [27]; 
bevacizumab + chemotherapy (6.3 months, 95% CI: 5.4, 7.2) vs single-agent treatment of physician’s 
choice (TPC) (approx. 60% capecitabine) (4.2 months, 95% CI: 3.9, 4.7), HR 0.75 (95% CI: 0.61, 
0.93), p=0.0068 [19]. 
In Keller et al, 2004 [31] pegylated liposomal doxorubicin showed no benefit over control therapy of 
either vinorelbine or mitomycin C + vinblastine (PFS 2.9 and 2.5 months, respectively; HR 1.26 (95% 
CI: 0.98, 1.62); p=0.11 [31]. 
Time to progression 
Of seven trials reporting TTP, three showed a significantly longer TTP: 3-weekly paclitaxel showed 
benefit over mitomycin (median TTP 3.5 vs 1.6 months, respectively; p=0.026) [21]; capecitabine + 
sorafenib was superior to capecitabine alone (median TTP 6.8 vs 4.1 months, respectively; HR 0.56 
[95% CI: 0.39, 0.8]; p=0.001) [29]; and nab-paclitaxel was associated with significantly greater TTP 
vs standard paclitaxel q3w (median TTP 4.8 vs 3.7 months, respectively; HR 0.73; p=0.02) [32].  
No benefit in terms of TTP was demonstrated for doxorubicin + vinorelbine vs doxorubicin 
monotherapy (TTP 4.3 vs 5.3 months, respectively) [24], for pegylated liposomal doxorubicin vs 
vinorelbine or mitomycin C + vinblastine (p>0.05) [31], for 3-weekly docetaxel vs vinorelbine (2.4 vs 
1.7 months, respectively; p=0.82) [30], or for epirubicin vs epirubicin + vindesine (TTP 6 months in 
both treatment arms) [25].  
Grade III+ adverse events, discontinuation and safety summary  
An overview of key safety results is shown in Table 5. Of the treatments or treatment combinations 
showing significant efficacy benefit, the only treatment with a demonstrated better overall safety 
profile was nab-paclitaxel vs 3-weekly standard paclitaxel [32]: although grade III sensory neuropathy 
occurred more frequently with nab-paclitaxel (10% vs 2%, respectively), treatment-related grade IV 
neutropenia was significantly lower on nab-paclitaxel (9% vs 22%, p<0.001), there were no grade 
III/IV hypersensitivity reactions with nab-paclitaxel (despite being no premedication in this arm) 
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whereas there were such reactions with standard paclitaxel (with premedication given), and AE-
related discontinuations and dose reductions or delays were low in both arms (3% with nab-paclitaxel 
and 7% on standard paclitaxel), as was febrile neutropenia (<2% in both arms). 
Low-dose (60mg/m2) docetaxel + capecitabine concomitantly, which had shown a PFS benefit vs 
docetaxel 70mg/m2 (prior to sequential capecitabine) showed non-significantly reduced 
haematological AEs, higher frequency of hand-foot syndrome (7.4% vs 0%, respectively) and lower 
frequencies of fatigue and peripheral oedema (Table 5) [27]. Paclitaxel 3qw had shown increased TTP 
vs mitomycin, but the safety profile was difficult to interpret because although taxane therapy was 
associated with more frequent grade III/IV neutropenia & peripheral neuropathy, patients received 
substantially more courses of PTX than mitomycin [21]. Thrombocytopenia was more common with 
mitomycin [21]. Sorafenib added to capecitabine had shown increased TTP and PFS, but was 
associated with a significantly higher frequency of grade III/IV hand-foot syndrome (44% vs 14% 
with monotherapy capecitabine) and discontinuation due to AEs (mainly hand-foot syndrome and 
diarrhoea) were higher also (20% vs 9%, respectively) [29]. The addition of bevacizumab to (mainly) 
capecitabine was beneficial to PFS, yet Grade III/IV AEs were more common with the combination 
treatment, mainly due to higher incidences of grade III hypertension and proteinuria. Discontinuation 
was also higher with the combination (Table 5) [19].  
Risk of bias assessment of second- and later-line trials (n=14) 
Of the 14 RCTs, 13 were full papers and so could be assessed for quality. Seven reported efficacy 
data on an intention-to-treat basis [19, 24, 25, 29, 31, 32, 34], randomisation was carried out 
appropriately in five [19, 22, 24, 26, 29, 34], but concealment of treatment allocation was unclear in 
most trials. Only one trial was double-blinded [29] and almost all trials did not have blinded outcome 
assessors. In terms of the distribution of patient characteristics between treatment groups, slight 
imbalances in potential prognostic factors were noted in six trials [20-24, 29]. Few trials reported 
confidence intervals around point estimates and only three confirmed HER2-negative status at 
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enrolment. No trial assessed or commented on discordant HER2 status between the primary tumour 
and metastases. 
Discussion 
To the best of our knowledge, this is the first SR to have been conducted to identify RCT evidence for 
the single-agent treatment of HER2-negative MBC at the second-line stage. Limited data are available 
for this setting: commercial sponsors are not enthusiastic; the market diminishes in size; and 
measurable outcomes are small. In addition, there is a clinical heterogeneity that accumulates due to 
prior treatment, performance status, and patient preferences. Only 14 trials reported data separately or 
were exclusively conducted in the second- or later-line setting.  
OS has long been regarded as the ‘gold standard’ measurement of clinical benefit in RCTs and is 
considered the primary measure of benefit in oncology [35]. Improvement in median OS is also 
considered an important outcome to determine clinical benefit of a new treatment compared with 
standard-of-care in the ASCO value framework proposed for advanced disease [36]. OS advantage is 
not easily demonstrable in this setting as the majority of RCTs are not usually sufficiently powered to 
detect OS benefits [37], longer follow-up is required [35], and estimates can be influenced by 
subsequent treatments once a particular trial has ended [37], details of which may not have been 
collected and reported.  
Of five trials demonstrating efficacy benefit (OS, PFS and/or TTP), only one showed significantly 
increased OS: nab-paclitaxel vs standard paclitaxel in the second- and later-line setting [32]. The 
survival benefit with nab-paclitaxel was realised with significantly less treatment-related grade IV 
neutropenia, and low levels of febrile neutropenia and AE-related discontinuation. The mature OS 
data from TANIA [19], examining the addition of bevacizumab to single-agent chemotherapy, are 
awaited. Much of the variation in absolute OS estimates can be explained by differences in the 
characteristics of enrolled patients, including ECOG status, crossover effects (not adjusted for) and 
whether second- or third-line patients were enrolled.  
  
15 
 
All of the larger trials had good aspects of quality, including intention-to-treat analysis. Although all 
were open-label, concealment of treatment allocation was largely not detailed and outcome assessors 
were not blinded. In two of the trials [31, 32], the randomisation method was not fully detailed, in that 
the sequence generation was not discussed. However both studies used stratification and there was no 
evidence of any imbalance between the treatment arms.  
As physicians rely on RCT data when deciding the most appropriate treatment for MBC patients 
failing first-line therapy [15], there is a need for high-quality RCT evidence specifically in the second-
line treatment of HER2-negative MBC patients, including OS estimation with adjustment for 
crossover effects [33], QoL estimation, and an understanding of patient preferences at this stage 
(whether the highest efficacy is of primary concern or whether the better safety profile of a single-
agent therapy is preferred). 
Two recent reviews in MBC have been published, Palumbo et al, 2013 [16] and Partridge et al, 2014 
[38], the latter providing the basis for the latest ASCO clinical practice guideline for ‘Chemo- and 
targeted therapy for women with HER2-negative (or unknown) advanced breast cancer’ [39]. In this 
study, the search strategy was limited to publications from 1993 onwards and did not include 
searching of the electronic database Embase; therefore this SR did not identify nine studies [20-26, 
30, 32], and most notably Gradishar et al. 2005 [32], demonstrating statistically significant OS benefit 
for nab-paclitaxel vs paclitaxel, was omitted from the ASCO guidelines [39]. Also not searched was 
PubMed for e-publications ahead of print, which identified the TANIA trial [19] in our SR.  
In Palumbo 2013, the search strategy is not detailed. Of the 14 trials we identified, Palumbo identified 
four [24, 26, 31, 32]. 
We did not include the IMELDA trial (Gligorov et al, 2014 [40]) as it focuses on maintenance of first-
line metastatic treatment response (i.e. progression-free patients), rather than on treating patients who 
have failed first-line metastatic treatment. The different nature of the patient population is reflected in 
the median OS values in the two treatment arms of 39.0 months on bevacizumab + capecitabine and 
23.7 months on bevacizumab alone. Further, we did not include Guan et al, 2009 [41] as the only data 
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reported specifically for the second- and later-line subgroup (n=85) was the clinical benefit rate, 
which was 51% with nab-paclitaxel (n=43) and 33% with standard paclitaxel (n=42), p=0.181. 
Outcomes of interest (OS, PFS, TTP and safety) were not reported for the second- or later-line 
subgroup. 
Classification of the line of therapy also appeared to be defined differently in these reviews than in 
our SR. Partridge et al, 2014 [38] included two studies as second-line; Cortes et al, 2011 [34] that was 
excluded from our SR because it enrolled patients with 2-5 prior chemotherapy treatments with two or 
more prior regimens for advanced disease and therefore represented a third- or later-line setting, and 
Keller et al, 2004 [31] that we classified as ‘second- or later-line’ because it enrolled patients with ‘no 
more than two chemotherapy regimens in the advanced setting (excluding adjuvant setting)’ and so 
would have included some third-line patients. Two other studies [27, 29], were classified as second-
line, whereas we classified these as uncertain second-line therapy as it was unclear if the second-line 
label related to chemotherapies or to the setting within metastatic disease. In Palumbo et al, 2013 [16], 
the line of therapy is seemingly classified according to the number of lines overall rather than by the 
number of lines within metastatic disease, meaning that the trials included are of a more 
heterogeneous nature than in our SR, as they will include trials with some patients who are first-line 
in the MBC setting. These distinctions are of importance as they help to better explain the OS and 
PFS data observed and, if papers provide not only median estimates but also the 95% confidence 
interval, then clinicians and patients will have more informative data on progression after failure of 
first-line treatment of metastatic disease upon which to base their treatment decision. 
One limitation to the methods employed in this SR is that, due to time constraints, we were only able 
to perform the second search update from October 2013 in PubMed, rather than conducting it in all 
the electronic databases. Comparison of outcomes between trials was hampered by the lack of 
common comparators across the evidence base, many of the single-agent therapies being compared 
with combination treatments, and heterogeneity (beyond line of therapy) being contributed further to 
by potential differential assignment of patients to trials, e.g. patients enrolled in capecitabine trials 
may, in general, have a lower disease burden than those in vinorelbine trials, varying chemotherapy 
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exposure (e.g. per-protocol maximum number of cycles and the dose reduction criteria applied to 
manage toxicity events), and varying schedule and cumulative dose across a cycle (e.g. the cumulative 
dose of a taxane administered across a cycle is known to predict neurotoxicity, with the 3-weekly 
schedule having a lower cumulative dose than weekly administration [42]). There was a distinct lack 
of QoL data that, in this setting, is a data gap, critical to be filled if clinical practice and patient 
decision-making is to be fully informed as well as reimbursement obtained [43].  
Conclusion  
There are few RCTs conducted specifically in the second-line HER2-negative MBC setting. Nab-
paclitaxel was the only single agent that demonstrated a survival advantage at the second-line and 
beyond. Few treatment options provide clinical benefit without adversely influencing tolerability. 
Given that MBC is an incurable disease and that an equally important aim of treatment at this stage is 
to enhance QoL and enable patients to be at home with their families, it is vital that trial investigators 
and clinicians set standards for the design and conduct of clinical trials with this aim in mind, with 
patients enrolled according to the treatment line received within the metastatic setting, with sufficient 
sample size to enable outcomes to be estimated with greater precision, with HER2-negative status and 
any discordant status established, a non-invasive method that has recently been tested in phase I [44], 
and with PROs recorded. This would contribute to physicians being able to more reliably inform 
patients regarding the likely range of treatment outcomes, and thereby help patients reach the 
treatment decision that is right for them.  
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Table 1: Trial characteristics of RCTs investigating second- and/or later-line therapy for metastatic disease (n=14) 
Line of therapy 
within metastatic 
setting 
First author, 
year 
Phase N  2nd line 
subgroup 
size 
Location Enrolment criteria HER2 status Primary 
endpoint 
2nd line Gasparini, 1991 NR 49 N/A Italy Progressing MBC after CMF with or 
without endocrine therapy. No prior 
anthracycline permitted. 
NR NR 
Dieras, 1995 II 81 N/A France Progressing MBC after one (metastatic) or 
two (metastatic and adjuvant) chemotherapy 
regimens. 
NR NR 
Venturino, 2000 II 99 N/A Italy Progressive MBC, one previous 
chemotherapy for metastatic disease. 
NR NR 
Papadimitriou, 
2009 
II 88 N/A Greece MBC patients, progressed after 1st line 
treatment with paclitaxel in metastatic 
setting. If HER2+, trastuzumab added to 
study treatment. 
21–24% HER2+, 
29–34% HER2–, 
34–42% 
unknown 
ORR 
Von Minckwitz, 
2014/TANIA 
III 494 N/A France, Hungary, Spain, 
Italy, Austria, Croatia, 
Germany, Switzerland, 
Slovakia, Greece, Israel, 
Argentina 
Locally recurrent or MBC patients, 
progressed after 1st line treatment with 
bevacizumab + chemotherapy. 
100% HER2– PFS  
2nd line (subgroup) Nielsen 1990, III 
 
143  75 Denmark Progressive ABC, with prior chemotherapy 
in either adjuvant or metastatic setting. 
NR NR 
Joensuu 1998, NR 303  162 Finland MBC patients without prior chemotherapy 
for metastatic disease, given either 
monotherapy or combination therapy in the 
1st line and then monotherapy or 
combination therapy in the 2nd line. Results 
reported for OS from second line. 
NR OS 
Norris 2000, III 303  NR Canada Only up to 1 prior chemotherapy for 
metastatic disease, or prior therapy in 
adjuvant setting. 
NR NR 
Unclear if 2nd line Baselga, 2012 III 229  116 Spain, France, Brazil LaBC or MBC, prior anthracycline and/or 
taxane in adjuvant or metastatic setting, max 
of 1 chemotherapy regimen in metastatic 
100% HER2– PFS 
  
Line of therapy 
within metastatic 
setting 
First author, 
year 
Phase N  2nd line 
subgroup 
size 
Location Enrolment criteria HER2 status Primary 
endpoint 
setting. (1st or 2nd line [45–57% 2nd line] 
overall in trial). 
[Note: reporting is not clear whether 2nd line 
relates to chemotherapy overall or to setting 
in metastatic disease] 
Sato, 2012 
(abstract) 
III 163 N/A Japan MBC patients previously treated with an 
anthracycline (though unclear if prior 
treatment was in adjuvant or metastatic 
setting from this abstract). 
100% HER2– PFS  
Ahmad, 2013 II 72 N/A India MBC patients who have failed previous 
chemotherapy (unclear if chemotherapy was 
given in adjuvant or metastatic setting). 
NR ORR 
2nd line or later Keller, 2004 III 301 N/A USA, Mexico, Europe LaBC or MBC (stage IIIb or IV), 
progression on a taxane during or within 6 
months of taxane therapy for advanced 
disease, no more than 2 chemotherapy 
regimens in the advanced setting (i.e. 
excluding adjuvant setting). 
NR PFS 
Palmieri, 2012 II 37 N/A UK MBC, progressive disease following 
anthracycline treatment (N.B. >80% were 
3rd line or later). 
Unselected, % 
NR 
OS 
2nd line or later 
(subgroup) 
Gradishar, 2005 III 460  268 USA/Canada, UK, 
Russia/Ukraine 
Mixed line enrolled (1st line, 2nd line, 3rd 
line, 4th line or more), 83% 1st or 2nd line, 
but 2nd or later line subgroup data reported 
separately. 
NR ORR 
Abbreviations: ABC, advanced breast cancer; CMF, cyclophosphamide, methotrexate, 5-fluorouracil; HER2+, human epidermal growth factor receptor 2-positive; HER2–, human epidermal growth factor 
receptor 2-negative; LaBC, locally advanced breast cancer; MBC, metastatic breast cancer; N/A, not applicable; NR, not reported; ORR, overall response rate; OS, overall survival; PFS, progression-free 
survival. 
  
  
Table 2. Patient characteristics of RCTs investigating second- and/or later-line therapy for metastatic disease (n=14) 
Line of 
therapy 
within 
metastatic 
setting 
First author, 
year 
Treatment 
arm 
N Median 
age, 
years 
ECOG status Race/ 
ethnicity of 
patients 
Metastatic 
sites/organs 
involved, n 
(%†) 
Any 
visceral 
disease, 
n (%) 
Liver 
metastases, 
n (%) 
Lung 
metastases, 
n (%) 
ER+, n 
(%) 
PR+, n 
(%) 
2nd line Gasparini, 
1991 
Epirubicin  25 60 NR; median KS 
80 
NR 1 site: 6 (27%) 
2 sites: 8 (36%) 
≥3 sites: 8 
(36%) 
9 (41%) NR NR NR NR 
Doxorubicin 24 55 NR 1 site: 7 (33%) 
2 sites: 7 (33%) 
≥3 sites: 7 
(33%) 
8 (38%) NR NR NR NR 
Dieras, 1995 PTX 175 q3w 41 52 0: 39%; 1: 51% 
2: 10% 
NR NR 33 (80%) 24 (59%) 14 (34%) NR NR 
Mitomycin 40 52.5 0: 45%; 1: 40%; 
2: 15% 
NR NR 38 (95%) 24 (60%) 18 (45%) NR NR 
Venturino, 
2000 
Vinorelbine  33 62.5 Median 0 (range 
0–1) 
NR NR 19 (58%) NR NR 14 
(42%) 
 
10 
(30%) 
Leucovorin 
then 5-FU 
33 60.0 Median 0 (range 
0–2) 
NR NR 23 (70%) NR NR 10 
(30%) 
8 
(24%) 
Mitoxantrone 
+ leucovorin 
then 5-FU 
33 60.5 Median 1 (range 
0–2) 
NR NR 22 (67%) NR NR 11 
(33%) 
10 
(30%) 
Papadimitriou, 
2009 
DTX 40 
weekly  
34 57 0: 71%; 1: 21%; 
2: 9% 
NR NR NR 19 (56%) 14 (41%) ER and PR 
positive: 25 
(74%) 
DTX 35 
weekly + 
GEM 
41 57 0: 56%; 1: 37%; 
2: 7% 
NR NR NR 21 (51%) 17 (42%) ER and PR 
positive: 27 
(66%) 
  
Line of 
therapy 
within 
metastatic 
setting 
First author, 
year 
Treatment 
arm 
N Median 
age, 
years 
ECOG status Race/ 
ethnicity of 
patients 
Metastatic 
sites/organs 
involved, n 
(%†) 
Any 
visceral 
disease, 
n (%) 
Liver 
metastases, 
n (%) 
Lung 
metastases, 
n (%) 
ER+, n 
(%) 
PR+, n 
(%) 
Von 
Minckwitz, 
2014/TANIA 
Bevacizumab 
+ 
chemotherapy  
247 56 0–2 NR but 
mainly 
Europe 
≥3 sites: 80 
(32%) 
186 
(75%) 
143 (58%) 70 (28%) ER+ and/or PR+: 
198 (80%) 
Single-agent 
chemotherapy 
(investigator’s 
choice) 
247 54 ≥3 sites: 88 
(36%) 
190 
(77%) 
151 (61%) 75 (30%) ER+ and/or PR+: 
188 (76%) 
Unclear if 
2nd line 
Sato, 2012 
(abstract) 
DTX 60 q3w 
+ CAPE  
82 NR 0 or 1 Japanese NR NR NR NR NR NR 
Sequential 
DTX 70 q3w 
until 
progression, 
followed by 
CAPE 
81 NR 0 or 1 NR NR NR NR NR NR 
Ahmad, 2013 DTX 75 q3w 23 45 0–2 Asian 
(India) 
NR NR NR NR NR NR 
Nanosomal 
DTX liquid 
suspension 
(75mg/m2) 
q3w  
49 47 0–2 NR NR NR NR NR NR 
2nd line 
(subgroup) 
Nielsen, 1990 Epirubicin   76 56 0–1: 76%; 2–3: 
24% 
NR 1 site: 38 (50%) 
2 sites: 27 
(36%) 
≥3 sites: 11 
(14%) 
NR 15 (20%) 23 (30%) ER or PR 
positive: 32 
(42%) 
  
Line of 
therapy 
within 
metastatic 
setting 
First author, 
year 
Treatment 
arm 
N Median 
age, 
years 
ECOG status Race/ 
ethnicity of 
patients 
Metastatic 
sites/organs 
involved, n 
(%†) 
Any 
visceral 
disease, 
n (%) 
Liver 
metastases, 
n (%) 
Lung 
metastases, 
n (%) 
ER+, n 
(%) 
PR+, n 
(%) 
Epirubicin + 
vindesine 
67 55 0–1: 78%; 2–3: 
22% 
NR 1 site: 33 (49%) 
2 sites: 27 
(40%) 
≥3 sites: 7 
(10%) 
NR 13 (19%) 21 (31%) ER or PR 
positive: 32 
(48%) 
Joensuu, 1998 Epirubicin 
then 
mitomycin 
150 56 WHO PS 
0: 19%; 1: 65% 
2: 16% 
NR NR NR 45 (29%) 39 (26%) 61 
(40%) 
NR 
CEF then 
mitomycin + 
vinblastine 
153 55 WHO PS 
0: 23%; 1: 63%; 
2: 14% 
NR NR NR 53 (35%) 43 (29%) 58 
(39%) 
NR 
Norris, 2000 Doxorubicin + 
vinorelbine  
151 55 0: 24%; 1–2: 
76% 
NR 1 site: 30 (20%) 
2 sites: 45 
(30%) 
≥3 sites: 76 
(50%) 
NR 68 (45%) 60 (40%) 85 
(56%)  
NR 
Doxorubicin 149 55 0: 24%; 1: 76% NR 1 site: 28 (19%) 
2 sites: 37 
(25%) 
≥3 sites: 84 
(56%) 
NR 66 (44%) 60 (40%) 74 
(50%) 
NR 
Baselga, 2012 Sorafenib + 
CAPE 
115 55.1 
(mean) 
0: 69%; 1: 30% White: 
85.2% 
Black: 4.3% 
Mestizo*: 
5.2% 
NR 87 
(75.7%) 
NR NR ER+ and/or PR+: 
94 (81.7%) 
  
Line of 
therapy 
within 
metastatic 
setting 
First author, 
year 
Treatment 
arm 
N Median 
age, 
years 
ECOG status Race/ 
ethnicity of 
patients 
Metastatic 
sites/organs 
involved, n 
(%†) 
Any 
visceral 
disease, 
n (%) 
Liver 
metastases, 
n (%) 
Lung 
metastases, 
n (%) 
ER+, n 
(%) 
PR+, n 
(%) 
Placebo + 
CAPE 
114 54.4 
(mean) 
0: 68%; 1: 30% White: 
86.0% 
Black: 6.1% 
Mestizo*: 
6.1% 
NR 84 
(73.7%) 
NR NR ER+ and/or PR+: 
79 (69.3%) 
2nd line or 
later 
Keller, 2004 PLD 150 56.0 KS 
60–70: 19% 
>70: 81% 
NR 1 site: 52 (35%) 
2 sites: 59 
(39%) 
≥3 sites: 39 
(26%) 
95 (63%) NR NR 71 
(47%) 
NR 
Vinorelbine or 
mitomycin C 
+ vinblastine 
151 56.0 KS 
60–70: 17% 
>70: 83% 
NR 1 site: 50 (33%) 
2 sites: 47 
(31%) 
≥3 sites: 52 
(34%) 
99 (66%) NR NR 72 
(48%) 
NR 
Palmieri, 2012 DTX 100 q3w 18 45 NR NR NR NR 7 (39%) 8 (44%) ER+ and PR+: 4 
(22%) 
ER+ and PR–: 7 
(39%) 
ER– and PR+: 1 
(5.6%) 
Vinorelbine 19 52 NR NR NR NR 4 (21%) 10 (53%) ER+ and PR+: 3 
(15.8%) 
ER+ and PR–: 6 
(31.6%) 
ER– and PR+: 2 
(10.5%) 
  
Line of 
therapy 
within 
metastatic 
setting 
First author, 
year 
Treatment 
arm 
N Median 
age, 
years 
ECOG status Race/ 
ethnicity of 
patients 
Metastatic 
sites/organs 
involved, n 
(%†) 
Any 
visceral 
disease, 
n (%) 
Liver 
metastases, 
n (%) 
Lung 
metastases, 
n (%) 
ER+, n 
(%) 
PR+, n 
(%) 
2nd line or 
later 
(subgroup) 
Gradishar, 
2005 
Nab-PTX 260 
q3w 
229 53.1 
(mean) 
0: 35%; 1: 59% 
2–3: 6% 
White: 97% 
Black: <1% 
Hispanic: 
1% 
S. Asian: 
0.9% 
Asian: <1% 
Other: <1% 
1 lesion: 3% 
2–3 lesions: 
18% 
>3 lesions: 79% 
176 
(76%) 
92 (40%) 74 (32%) NR NR 
PTX 175 q3w 225 53.3 
(mean) 
0: 36%; 1: 61%; 
2–3: 2% 
White: 97% 
Black: 2% 
Hispanic: 
<1% 
S. Asian: 0% 
Asian: 0% 
Other: 0% 
1 lesion: 4% 
2–3 lesions: 
24% 
>3 lesions: 72% 
182 
(81%) 
97 (43%) 79 (35%) NR NR 
Abbreviations: CAPE, capecitabine; CEF, cyclophosphamide, epirubicin and 5-fluorouracil; DTX, docetaxel; ECOG, Eastern Cooperative Oncology Group; ER, oestrogen receptor; FU, fluorouracil; GEM, 
gemcitabine; KS, Karnovsky Score; NR, not reported; PLD, pegylated liposomal doxorubicin; PR, progesterone receptor; PS, performance status; PTX, paclitaxel; q3w, three-weekly; WHO, World Health 
Organization. 
*A person of mixed European and Native American ancestry 
†May not total 100%, due to either the effect of rounding or reported missing patient data within an RCT. 
 
 
  
  
Table 3: Overall survival in second- and/or later-line setting 
Line of therapy within metastatic setting First author, year Treatment arms N 
Median OS, 
months (95% 
CIs) 
HR (95% 
CIs), p-value 
2nd line 
Gasparini, 1991 
Epirubicin 22 12 
– 
Doxorubicin 21 11 
Dieras, 1995 
Paclitaxel 175 mg/m2, q3w 41 12.7 
p=0.15 
Mitomycin 40 8.4 
Venturino, 2000 
Vinorelbine 33 9.5 
– 
 
Leucovorin then  5-fluorouracil 33 9 
Mitoxantrone + leucovorin then 5-fluorouracil 33 9 
Papadimitriou, 2009 
DTX weekly 34 28 (15.7, 40.3) 
p=0.41 
DTX + gemcitabine 41 14 (3, 25) 
Von Minckwitz, 2014/TANIA 
Bevacizumab + chemotherapy  247 NR: OS data immature, data to be 
reported in future publication Single-agent chemotherapy (investigator’s choice) 247 
2nd line (subgroup) 
Nielsen, 1990 
Epirubicin 42 12  
– 
Epirubicin + vindesine 33 12  
Joensuu, 1998 
Epirubicin then mitomycin 74 10 Non-
significant CEF then mitomycin + vinblastine 88 8 
Norris, 2000 
Doxorubicin + vinorelbine NR 9.4 
– 
Doxorubicin NR 11.3 
Unclear if 2nd line 
Baselga, 2012 
CAPE + sorafenib 65 19 1.08 (0.65, 
1.78) CAPE + placebo 51 23.4 
Sato, 2012 
DTX 60 q3w + CAPE 82 
NR. OS data immature 
Sequential DTX 70 q3w until progression, then CAPE 81 
  
Line of therapy within metastatic setting First author, year Treatment arms N 
Median OS, 
months (95% 
CIs) 
HR (95% 
CIs), p-value 
2nd line or later 
Keller, 2004 
Pegylated liposomal doxorubicin 150 10.4 1.07 (0.79, 
1.45), p=0.57 Control: vinorelbine OR mitomycin C + vinblastine 151 9 
Palmieri, 2012 
DTX q3w 16 7.8 (4.8, 11)†† 
p=0.388 
Vinorelbine 18 4.9 (3.9, 5.8)†† 
2nd line or later (subgroup) Gradishar, 2005 ABI-007 (nab-paclitaxel) 131 13.0
††
 
0.73, p=0.024 
Paclitaxel 175 mg/m2, 3 weekly 136 10.7†† 
Abbreviations: CAPE, capecitabine; CEF, cyclophosphamide, epirubicin and 5-fluorouracil; CI, confidence interval; DTX, docetaxel; HR, hazard ratio; NR, not reported; OS, overall survival; q3w, three-
weekly. 
††Calculated (converted from weeks to months) 
N.B. OS data not reported in Ahmad 2013 
 
 
  
  
Table 4. Median OS (months) in second- and/or later-line setting 
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Nielsen 1990       12      12       
Gasparini 1991       12  11           
Dieras 1995   12.7        8.4         
Joensuu 1998*        10        8    
Venturino 2000  9.5                9 9 
Norris 2000         11.3      9.4     
Keller 2004          10.4       9   
Gradishar 2005†   10.7 13                
Papadimitriou 2009      28        14      
Baselga et al. 2012§ 23.4           19        
Palmieri 2012**  4.9   7.8               
 
  
Abbreviations: CAPE, capecitabine; VIN, vinorelbine; PTX, paclitaxel; DTX, docetaxel; DOX, doxorubicin; PLD, pegylated liposomal doxorubicin; GEM, gemcitabine; FEC, fluorouracil, 
epirubicin and cyclophosphamide; PTX, paclitaxel;  5-FU, 5-flourouracil; Leu, leucovorin 
*10 month OS value calculated (from value in weeks reported in paper) 
†13 month OS value calculated (from value in weeks reported in paper). OS is statistically significantly longer with Nab-PTX vs standard PTX 3-weekly. 
§Unclear line of therapy. Reportedly second line but unclear whether first line was in adjuvant and/or metastatic setting. 
**Over 80% of patients were third- or later-line 
N.B. No OS data was reported in Ahmad 2013. OS data was immature and so not reported yet in Sato 2012 and in von Minckwitz 2014/TANIA.  
 
  
  
Table 5. Grade 3+ toxicities, withdrawal & safety summary in second- and/or later-line setting 
Line of 
therapy 
within 
metastatic 
setting 
First Author 
Year 
Treatment 
arms 
N‡ Key grade III/IV toxicities (%) Withdrawals due 
to AEs 
Summary of safety 
2nd line Gasparini 1991 Epirubicin 22 Leukopenia 0% 
Thrombocytopenia 0% 
 
NR Considering all grade AEs leukopenia and 
thrombocytopenia significantly more frequent 
on doxorubicin. Significantly greater 
frequency of dose delays due to 
haematological AEs with doxorubicin. 
Doxorubicin 21 Leukopenia 5% (1 patient, grade III) 
Thrombocytopenia 0% 
 
NR 
Dieras 1995 Paclitaxel 175 
mg/m2 q3w 
41 Neutropenia 61% 
Peripheral neuropathy 11% 
Thrombocytopenia 3% 
 
4 patients due to 
peripheral 
neuropathy 
Neutropenia & peripheral neuropathy more 
frequent on PTX but patients received more 
courses of PTX than mitomycin. 
Thrombocytopenia more common with 
mitomycin. 
Febrile neutropenia occurred in 1 patient (3%) 
on PTX 
Mitomycin 40 Neutropenia 3% 
Neuropathy 0% 
Thrombocytopenia 20% 
1 patient due to 
persistent 
neutropenia 
Venturino 2000 Vinorelbine 33 Anaemia 3% 
Leukopenia 18% 
Thrombocytopenia 0% 
Diarrhoea 0% 
Paralitic ileus 3% 
Any grade III AE 27% 
NR Lower incidence of grade III/IV toxicities in 
mitoxantrone combination arm. 
Authors consider that it is not always the 
single agent therapy that is best tolerated and 
that analysis of QoL, pain and symptom 
control (nausea, fatigue, improvement in 
performance status) is needed in trials in 
patients with incurable cancers, and 
comparison with best supportive care. 
 
Leucovorin 
then  5-
fluorouracil 
33 Anaemia 0% 
Leukopenia 3% 
Thrombocytopenia 0% 
Diarrhoea 12% 
Paralitic ileus 0% 
Any grade III AE 15% 
NR 
Mitoxantrone + 
leucovorin then 
5-fluorouracil 
33 Anaemia 0% 
Leukopenia 3% 
Thrombocytopenia 3% 
Diarrhoea 0% 
Paralitic ileus 0% 
Any grade III AE 18% 
NR 
  
Line of 
therapy 
within 
metastatic 
setting 
First Author 
Year 
Treatment 
arms 
N‡ Key grade III/IV toxicities (%) Withdrawals due 
to AEs 
Summary of safety 
Papadimitriou 
2009 
Docetaxel 40 
mg/m2 weekly 
30 Anaemia 0% 
Neutropenia 3% 
Thrombocytopenia 3% 
Leukopenia 10% 
Stomatitis 10% 
Diarrhoea 3% 
Alopecia 13% 
Any grade III/IV AE 3% 
NR Higher frequency of grade III/IV neutropenia 
with DTX+GEM (23%) vs DTX (3%) 
(p=0.035). Such patients received G-CSF. 
Grade I or II febrile neutropenia occurred in 
41% with DTX+GEM vs 23% with DTX. 
Docetaxel 35 
mg/m2 + 
gemcitabine 
39 Anaemia 5% 
Neutropenia 23% 
Thrombocytopenia 6% 
Leukopenia 18% 
Stomatitis 3% 
Diarrhoea 0% 
Alopecia 23% 
Any grade III/IV AE 23% 
NR 
Von Minckwitz 
2014/TANIA 
Bevacizumab + 
chemotherapy 
245 Any grade III/IV AE 59% 
Grade III hypertension 13% 
Proteinuria 7% 
18% discontinued 
BEV, mostly for 
proteinuria, 
venous embolism 
and pulmonary 
embolism 
16% discontinued 
chemotherapy 
Grade III/IV AEs more common with 
combination treatment, mainly due to higher 
frequency of grade III hypertension and 
proteinuria 
 
AE leading to chemotherapy discontinuation 
in >2% of patients was hand-foot syndrome in 
BEV+chemotherapy group, all of whom were 
receiving capecitabine Single-agent 
chemotherapy 
(investigator’s 
choice) 
238 Any grade III/IV AE 46% 
Grade III hypertension 7% 
Proteinuria <1% 
8% discontinued 
chemotherapy 
2nd line 
(subgroup) 
Nielsen 1990 Epirubicin 42 NR for subgroup NR for subgroup NR for subgroup but overall: 
thrombocytopenia significantly less frequent 
on epirubicin plus vindesine vs epirubicin 
monotherapy (p<0.01); mild-moderate 
peripheral neuropathy occurred in 40% of 
Epirubicin + 
vindesine 
33 
  
Line of 
therapy 
within 
metastatic 
setting 
First Author 
Year 
Treatment 
arms 
N‡ Key grade III/IV toxicities (%) Withdrawals due 
to AEs 
Summary of safety 
patients on combination therapy; 9 patients on 
epirubicin & 6 on combination had febrile 
neutropenia. CHF occurred in on epatient with 
cumulative dose of epirubicin <1000 mg/m2 
and 7/15 patients with >1000 mg/m2; 4 
patients died from CHF. 
Joensuu 1998 Epirubicin (1st 
line) then 
mitomycin (2nd 
line) 
74 NR for 2nd line subgroup 8 patients 
discontinued M 
(12%) 
Significantly greater frequency of toxicity 
with mitomycin + vinblastine vs mitomycin 
single-agent therapy, due to more leukopenia 
(p=0.005), nausea or vomiting (p=0.01), 
alopecia (p=0.003) and tendency for more 
anaemia (p=0.07). No difference in frequency 
of thrombocytopenia (p=0.28) 
CEF (1st line) 
then mitomycin 
+ vinblastine 
(2nd line) 
88 NR for 2nd line subgroup 17 patients 
discontinued MV 
(20%) 
Norris 2000 Doxorubicin + 
vinorelbine 
NR NR for subgroup NR for subgroup NR for subgroup. However, in the overall 
population greater incidences of Grade 3/4 
neurotoxicity, mild venous toxicity and febrile 
neutropenia were observed in the doxorubicin 
+ vinorelbine arm. 11% of patients in 
combination arm discontinued vs. 4% in 
monotherapy arm. 
Doxorubicin NR NR for subgroup NR for subgroup 
Unclear if 2nd 
line 
Baselga 2012 Capecitabine + 
sorafenib 
65 HFSR/HFS 44% (Grade III) 20% discontinued, 
mainly due to 
HFSR/HFS (9 
patients) and 
diarrhoea (1 
patient) 
Grade III/IV HFSR/HFS occurred 
significantly more frequently with sorafenib 
than with placebo. With all grade HFSR/HFS 
it also occurred earlier with sorafenib (median 
14 days to first occurrence vs 64 days) 
HFSR/HFS potentially impacts QoL and 
treatment changes. 
 
Other grade III/IV events occurred with 
similar frequency in treatment arms. 
 
All grade AEs were numerically higher with 
Capecitabine + 
placebo 
51 HFSR/HFS 14% (Grade III) 9% discontinued, 
mainly due to 
HFSR/HFS (4 
patients) and 
diarrhoea (3 
patients) 
  
Line of 
therapy 
within 
metastatic 
setting 
First Author 
Year 
Treatment 
arms 
N‡ Key grade III/IV toxicities (%) Withdrawals due 
to AEs 
Summary of safety 
sorafenib for diarrhoea, mucosal 
inflammation, rash, neutropenia, hypertension 
and HFSR/HFS. 
 
Dose delays and reductions to manage 
toxicities more frequent with sorafenib. 
Sato 2012 DTX 60 3-
weekly + 
CAPE 
82 Decreased neutrophil count 57.3% 
Neutropenia 8.5% 
Febrile neutropenia 6.1% 
NR ADRs with at least 5% difference in 
frequency were HFS (7.3% vs. 0%), fatigue 
(2.4% vs. 8.8%) and peripheral edema (1.2% 
vs. 6.3%) in the concurrent vs. sequential 
groups. 
Sequential 
DTX 70 3-
weekly until 
progression, 
then CAPE 
81 Decreased neutrophil count 60.0% 
Neutropenia 12.5% 
Febrile neutropenia 10.0% 
NR 
2nd line or 
later 
Keller 2004 Pegylated 
liposomal 
doxorubicin 50 
mg/m2 q4w 
150 Leukopenia 20% 
Neutropenia 2% 
Febrile neutropenia 0 patients 
PPE 18% grade III, 1 patient grade IV 
LVEF changes consistent with cardiac 
toxicity in 22 patients 
4 discontinued due 
to LVEF changes 
Myelosuppression was lower with PLD: grade 
III/IV leukopenia less frequent with PLD than 
with control group, and grade III/IV 
neutropenia less frequent with PLD than with 
vinorelbine. 
 
Most common ADR with PLD was palmar-
plantar erythrodysesthesia (37% any grade). 
Infusion reactions and any grade stomatitis 
were more common with PLD. 
 
Control: 
vinorelbine 
151 Leukopenia 54% 
Neutropenia 8% 
Febrile neutropenia 2 patients 
Unclear 
Control: 
mitomycin C + 
vinblastine 
 Leukopenia 30% 
Febrile neutropenia 0 patients 
Unclear 
Palmieri 2012 Docetaxel 100 
mg/m2 q3w 
18 Grade III/IV AEs 27 events 
Grade III/IV haematological AEs and 
infections 20 events 
High rate of 
discontinuation or 
interruption of 
treatment (% 
unspecified) 
Grade III/IV toxicity (in particular 
haematological AEs and infections) more 
frequent with DTX than with vinorelbine. 
 
Vinorelbine 25 
mg/m2 q2w 
18 Grade III/IV AEs 4 events 
Grade III/IV haematological AEs and 
 
  
Line of 
therapy 
within 
metastatic 
setting 
First Author 
Year 
Treatment 
arms 
N‡ Key grade III/IV toxicities (%) Withdrawals due 
to AEs 
Summary of safety 
infections 2 events 
2nd line or 
later 
(subgroup) 
Gradishar 2005 ABI-007 (nab-
paclitaxel) 
131 NR for subgroup NR for subgroup Subgroup analyses reported showed that 
safety profiles of 1st line patients similar to 
those of 1st and 2nd/later line overall 
population. 
Treatment-related grade IV neutropenia 
significantly lower on nab-paclitaxel (9%) 
than on standard paclitaxel (22%), p<0.001, 
enabling the dose to be increased by 50%. 
Febrile neutropenia <2% in both arms. 
 
Grade III sensory neuropathy 10% with nab-
paclitaxel vs. 2% with standard paclitaxel, but 
easily managed with dose interruption or 
reduction. 
 
No grade III/IV hypersensitivity reactions to 
nab-paclitaxel (in spite of no premedication) 
whereas they did occur with standard 
paclitaxel despite premedication. 
 
AE-related discontinuations, dose reductions 
and dose delays were low frequency in both 
arms (3% with nab-paclitaxel and 7% on 
standard paclitaxel). 
Paclitaxel 175 
mg/m2 q3w 
136 NR for subgroup NR for subgroup 
ADR, adverse drug reaction (treatment-related adverse event); CEF, cyclophosphamide, epirubicin and fluorouracil; CR, complete response; ER, estrogen receptor; M, mitomycin; MV, 
mitomycin + vinblastine; NR, not reported; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, progesterone receptor; PRe, partial 
response; QoL, quality of life; SD, stable disease; TTP, time to progression 
†May not total 100%, due to either the effect of rounding or reported missing patient data within an RCT. 
††Calculated (converted from weeks to months) 
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Highlights: 
• Line of therapy terminology is imprecise 
• Median OS from second-line MBC estimated from larger trials is 8–13 months 
• Only one RCT has shown significant efficacy benefit alongside favourable safety 
• As single agent, nab-paclitaxel has demonstrated significant OS benefit. 
• QoL data and precise OS estimation are needed according to patient characteristics 
 
 
